Fortis Healthcare Ltd (FHL), promoted by the promoters of Ranbaxy Laboratories, has filed its Draft Red Herring Prospectus with its proposal to enter the capital market. The company is planning to offer 5.67 lakh equity shares of Rs10 each for cash at a premium to be decided through the 100 per cent book-building process. The shares will be listed on the BSE and NSE.
FHL is also allotting 5 lakh equity shares to eligible employees of the company in the firm allotment portion.
Of the net offer to the public, the company will offer 60 per cent of the total issue qualified institutional buyers on a proportionate basis, 5 per cent of which will be available for allotment to mutual funds registered with the SEBI.
FHL currently has a network of 12 hospitals primarily in North India and 15 satellite and heart command centers in hospitals across the country and one heart command centre in Afghanistan. The hospitals include multi specialty hospitals, as well as super-specialty "centers of excellence" providing tertiary and quaternary healthcare to patients in key areas such as cardiac care, orthopaedics, neuro-sciences, renal care, pulmono -thoracic surgery and diabetic care. Besides these, the company also manages Fortis La Femme, a "boutique" style hospital that focuses on women's health and maternity care.
The book running lead managers to the issue are JM Morgan Stanley, Citigroup Global Markets India and Kotak Mahindra Capital Company.